New study in @jamanetworkopen.com this week: frequency of post-market safety issues for cancer drugs with accelerated approval.
Happy to collaborate on this study with Dr. Mooghali, @reshmagar.bsky.social @jsross119.bsky.social
jamanetwork.com/journals/jam...
This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.
